Product
AZD7442
Aliases
AZD7442 IM, AZD7442 IV, AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]), AZD8895 + AZD1061 (1 other aliases)
12 clinical trials
2 indications
Indication
COVID-19Indication
Healthy VolunteerClinical trial
Open-Label, Uncontrolled, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 YearsStatus: Active (not recruiting), Estimated PCD: 2024-03-29
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19.Status: Completed, Estimated PCD: 2022-08-16
Clinical trial
Phase 1, Randomized, Open Label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 + AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation Versus Administration From Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19Status: Active (not recruiting), Estimated PCD: 2023-09-07
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized AdultsStatus: Completed, Estimated PCD: 2021-08-21
Clinical trial
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19Status: Terminated, Estimated PCD: 2023-10-04
Clinical trial
A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese AdultsStatus: Completed, Estimated PCD: 2021-11-27
Clinical trial
A Phase II Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese AdultsStatus: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19Status: Completed, Estimated PCD: 2021-04-07
Clinical trial
Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)Status: Completed, Estimated PCD: 2022-04-07
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19Status: Completed, Estimated PCD: 2022-04-06
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H4: AZD7442)Status: Active (not recruiting), Estimated PCD: 2022-01-28